Biomarker Profiling of Radiation and DDR Inhibitor Combinations in LNCaP Xenografts

AACR 2026 Poster | Ionising radiation induces DNA damage primarily through the formation of single and double strand breaks, which, if unrepaired, can lead to cell death. These breaks activate the DNA damage response. (DDR) which is a network of cellular pathways that detect and repair any DNA damage and includes the phosphorylation of proteins like H2AX and DNA-PK.

When damage is extensive or incorrectly repaired, this can result in genomic instability, apoptosis, or senescence. In drug discovery, this mechanism can be exploited by combining targeted delivery of ionising radiation to cancer cells with inhibition of key DDR proteins, thereby preventing repair and promoting tumour cell death.

Biomarkers of radiosensitivity and DNA damage are therefore critical for both preclinical and clinical evaluation of novel combination therapies.

Meet the team at AACR 2026 at Booth 1418, Hall C (Ground Level).


Scientist in lab



View the poster here

 

 







News
03 September 2026
Medicines Discovery Catapult invests in UK biotech pioneers developing novel treatments for chronic diseases

Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.


News
22 July 2026
UK Intracellular Drug Delivery Centre opens for industry access to accelerate next-generation RNA medicines 

The centre will provide integrated expertise and evidence generation to help innovators accelerate the development of next-generation RNA medicines.





Medicines Discovery Catapult